• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, July 27

Drug-maker Nicholas Piramal India Ltd has received regulatory approval in the US for its Investigational New Drug IND-P276, its lead cancer compound to treat Multiple Myeloma, a form of blood cancer.

Clinical trials, during which the prospective drug is tested on humans, will start at Harvard University's Dana Farber Cancer Institute, the company told the BSE. Two additional sites - St. Vincent's Hospital, New York and Emory University Medical Center in Atlanta will also participate in this study.

Stating that the US Food and Drug Administration has approved the IND application, the company said that it’s a first from India in the cancer segment.

Multiple Myeloma (MM) is the second most common hematologic malignancy, responsible for at least 2 per cent of cancer-related deaths.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Nicholas Piramal gets US nod for cancer compound

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line